Safety, tolerability and efficacy of the new phosphodiesterase inhibitor roflumilast (B9302107) administered to asthmatic subjects as repeated oral doses over 4 weeks

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

Phase 1, mono-center, double-blind, randomized, placebo-controlled, two-period crossover study in asthmatic subjects.